The latest update is out from Day One Biopharmaceuticals (DAWN).
Day One Biopharmaceuticals, Inc. has refreshed its corporate presentation to reflect the latest developments in its FIREFLY-2 trial, focusing on tovorafenib as a treatment for pediatric low-grade glioma. The company announced significant trial modifications, including changes to primary and key secondary endpoints, an updated dosing regimen, and an additional standard of care option. These updates stem from FDA feedback and aim to enhance the evaluation of tovorafenib’s effectiveness for young patients battling this form of cancer.
Learn more about DAWN stock on TipRanks’ Stock Analysis page.
